Fluoro-A 85380 | 186588-98-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Fluoro-A 85380
• 英文别名: 2-fluoro-3-[(S)-2-azetidinylmethoxy]pyridine；F-A-85380；2-Fluoro-A-85380；3-[[(2S)-azetidin-2-yl]methoxy]-2-fluoropyridine
• CAS: 186588-98-7
• 化学式: C₉H₁₁FN₂O
• 分子量: 182.198
• InChiKey: GVOOYVOZPRROMP-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Fluoro-A 85380 以 氘代二甲亚砜 为溶剂， 反应 0.75h， 生成 (S)-1,2,2a,3-Tetrahydro-4-oxa-8,8b-diaza-cyclobuta[a]naphthalene
  参考文献：
  名称：

  Synthesis of 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors

  摘要：

  This paper reports the synthesis of 2-fluoro-3-[2(S)-2-azetidinylmethoxyl] and its radiolabeling with fluorine-18 ([F-18]FK-K-222) by nucleophilic aromatic nitro-to-fluoro substitution in DMSO by conventional heating at 150 degrees C for 20 min or by microwave activation at 100 Watt For 1 min. This fluoro compound is a closely related analog of the high affinity nicotinic ligand A-85380 (3-[2(S)-2-azetidinylmethoxy]pyridine) This compound is the lead compound of a novel 3-pyridyl ether series sf new nAChR ligands recently published, and possesses not only subnanomolar affinity, comparable to that of epibatidine, for the alpha 4 beta 2 subtype, but also a weaker affinity for the other subtypes of nAChRs. 110-140 mCi (4. -5.2 GBq) of pure 2-[F-18]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine ([F-18]fluoro-A-85380) could be obtained in less than 2 !lours, with specific radioactivities of 3-5 Ci/mu mol (111-185 GBq/mu mol) calculated for End of Bombardment (or 1.5-2.5 Ci/mu mol (55.5-92.5 GBq/mu mol) at End of Synthesis) for a 20 mu A, 30 min (36000 mu C) irradiation of a 95% enriched [O-18]water target with a 16 MeV proton beam [O-18(p,n)F-18]. Yields (with respect to [F-18]fluoride ion) : decay-corrected 49-64%; non-decay-corrected 25-33%. Total synthesis rime from EOB : 105-110 min (this includes the recovery of the [F-18]fluoride ion from the target and the [F-18]FK-K-222-complex preparation). Preliminary results in rats showed a substantial uptake of the ligand in the thalamus (1% I.D./g tissue at 30 min) while the cerebellar uptake was 2-fold lower. Thalamic uptake was reduced by 75-85% following a pretreatment with nicotine, cytisine, epibatidine or fluoro-A-85380. The full pharmacological profile and the potential for eventual clinical applications of this ligand as a tracer for PET experiments are currently under investigation.

  DOI：

  10.1002/(sici)1099-1344(199805)41:5<451::aid-jlcr111>3.0.co;2-r
• 作为产物：
  描述：

  3-羟基-2-碘吡啶 在 potassium fluoride 、 氢溴酸 、 N,N'-二环己基碳二亚胺 、 三苯基膦 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 、 三氟乙酸 、 copper(l) chloride 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 溶剂黄146 、 二甲基亚砜 为溶剂， 反应 156.0h， 生成 Fluoro-A 85380
  参考文献：
  名称：

  Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]A-85380)

  摘要：

  The radiochemical synthesis of 2-[F-18]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[F-18]A-85380, [F-18](1) under bar 1) was accomplished by Kryptofix(R) 222 assisted nucleophilic no-carrier-added [F-18]fluorination of 2-iodo-3-((1-tert-butoxycarbonyl-2 -(S)-azetidinyl)methoxy)pyridine, (2) under bar followed by acidic deprotection. The average radiochemical yield was 10% and the average specific radioactivity was 1050 mCi/mu mol, calculated at end-of-synthesis (EOS).

  DOI：

  10.1002/(sici)1099-1344(199804)41:4<309::aid-jlcr78>3.0.co;2-i

文献信息

• Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP2085390A1

  公开（公告）日：2009-08-05

  The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen atom, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1-Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ):          -(CH2)t-     (β) R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (y):          -Y-Z-W-R11     (γ) wherein R11 represents an optionally labelled halogen atom, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen atom, a radionuclide, a -NO2 group, a -NR5R6 group, a -N+R5R6R7X- group, or a -OSO2R12 group, and their addition salts with pharmaceutically acceptable acids. The present invention also relates to pharmaceutical compositions comprising them and to their use in diagnosis, in particular with SPECT, PET and in therapy.

  本发明涉及以下式（I）的化合物： 其中 R1代表氢原子，可选择标记的卤原子，放射性核素或Sn[(C1-C4)烷基]3基团， Ar代表芳基团或杂芳基团， R9代表氢原子，(C1-C4)烷基团或与基团R1-Ar一起形成与Ar基团融合的环， A代表以下式（β）或（δ）的基团：          -(CH2)t-     (β) R3和R4独立地代表氢原子，(C1-C6)烷基团，(C1-C6)烯基团或以下式（γ）的基团：          -Y-Z-W-R11     (γ) 其中R11代表可选择标记的卤原子，放射性核素，芳基或杂芳基团，可选择地被可选择标记的卤原子，放射性核素，-NO2基团，-NR5R6基团，-N+R5R6R7X-基团或-OSO2R12基团取代，并且它们与药学上可接受的酸形成的加合盐。 本发明还涉及包含它们的药物组合物以及它们在诊断中的使用，特别是在单光子发射计算机断层扫描（SPECT）、正电子发射断层扫描（PET）和治疗中的使用。
• Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
  申请人：Institut National de la Santé et de la Recherche Médicale

  公开号：EP2657213A1

  公开（公告）日：2013-10-30

  The present invention relates to the compound of formula (I): in which R1 represents Sn(R)3, B(OH)2, B(OR)2, a halogen atom, NO2, a radionuclide or a -N+(R)3 group, where R is a (C1-C6) alkyl group, R2 represents a hydrogen atom or a (C1-C6)alkyl group, R3 represents: - a -(CH2CH2O)n2-(CH2)n3-X group, or - a ―(CH2CH2O)n4-(CH2)n5-Y group with Y representing a -C=C-H, a -N3 or a -Ar-(CH2)n6-(OCH2CH2)n7-X group, and X represents a halogen atom, a radionuclide or a -OSO2R' group, where R' is a CF3, CH3, t-Bu, Ph, p-NO2Ph, p-BrPh or p-CH3Ph group, and their addition salts with pharmaceutically acceptable acids, The present invention also relates to pharmaceutical compositions comprising them and to their use in diagnosis, in particular with SPECT or PET imaging and in therapy of melanoma, via targeted radionuclide therapy.

  本发明涉及具有以下结构的化合物（I）： 其中 R1代表Sn（R）3，B（OH）2，B（OR）2，卤素原子，NO2，放射性核素或-N+（R）3基团，其中R是（C1-C6）烷基基团， R2代表氢原子或（C1-C6）烷基基团， R3代表： - 一个-(CH2CH2O)n2-(CH2)n3-X基团，或 - 一个―(CH2CH2O)n4-(CH2)n5-Y基团，其中Y代表-C=C-H，-N3或-Ar-(CH2)n6-(OCH2CH2)n7-X基团，而X代表卤素原子，放射性核素或-OSO2R'基团，其中R'是CF3，CH3，t-Bu，Ph，p-NO2Ph，p-BrPh或p-CH3Ph基团，并且它们与药学上可接受的酸形成的加合盐， 本发明还涉及包含它们的药物组合物，以及它们在诊断中的使用，特别是与SPECT或PET成像一起以及在黑色素瘤的治疗中，通过靶向放射性核素治疗。
• Radiolabelled MMP selective compounds
  申请人：Academisch Medisch Centrum bij de Universiteit van Amsterdam

  公开号：EP2119690A1

  公开（公告）日：2009-11-18

  The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH2, (CH2)2, S, NH, or C(=O)NH; X represents 1-5 substituents, wherein said substituents can be the same or different and wherein at least one of said substituents comprises a radioisotope suitable for PET and/or SPECT and/or a β-emitter; Z is S or P; Q is chosen from the group consisting of 3-pyridyl and carboxyl; and R is chosen from the group consisting of C(=O)-NH-OH, The MMP selective compounds of the invention are selective for MMPs and can be used for the identification and treatment of unstable atherosclerotic plaques

  该发明涉及放射标记的MMP选择性化合物，其制备方法以及用途。该发明的衍生物具有以下式（I）其中Y代表O、CH2、（CH2）2、S、NH或C（=O）NH；X代表1-5个取代基，其中所述取代基可以相同也可以不同，并且其中至少一个取代基包含适用于PET和/或SPECT和/或β发射子的放射性同位素；Z为S或P；Q选择自3-吡啶基和羧基组成的群；R选择自C（=O）-NH-OH组成的群。该发明的MMP选择性化合物对MMPs具有选择性，并可用于识别和治疗不稳定的动脉粥样硬化斑块。
• Labeled ALPHA4BETA2 Ligands and Methods Therefor
  申请人：Mukherjee Jogeshwar

  公开号：US20090297443A1

  公开（公告）日：2009-12-03

  Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction.

  思考的组合和方法被用于高度选择性地在体外和体内与α4β2尼古丁乙酰胆碱受体结合。如果这些化合物被标记，使用这些化合物的组合和方法可以用于PET和SPECT分析。另外，或者还可以将思考的化合物用作α4ββ2功能失调相关疾病或病情的拮抗剂、部分激动剂或激动剂的治疗。
• LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS
  申请人：Chezal Jean-Michel

  公开号：US20110044899A1

  公开（公告）日：2011-02-24

  A compound of formula (I): in which R 1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C 1 -C 4 )alkyl] 3 group, Ar represents an aryl group or a heteroaryl group, R 9 represents a hydrogen atom, a (C 1 -C 4 ) alkyl group or forms together with the group R 1 —Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ): R 3 and R 4 independently represent a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 ) alkenyl group or a group of formula (y): wherein R 11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO 2 group, a —NR 5 R 6 group, a N + R 5 R 6 R 7 X − group, or a —OSO 2 R 12 group, and their addition salts with pharmaceutically acceptable acids.

  化合物的化学式为(I)：其中R1代表氢原子、可选择标记的卤素、放射性核素或Sn[(C1-C4)烷基]3基团，Ar代表芳基或杂芳基，R9代表氢原子、(C1-C4)烷基或与基团R1-Ar共同形成与Ar基团融合的环，A代表化学式(β)或(δ)的基团：R3和R4分别独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或化学式(y)的基团：其中R11代表可选择标记的卤素、放射性核素、可选择取代的芳基或杂芳基，取代基可以是可选择标记的卤素、放射性核素、—NO2基团、—NR5R6基团、N+R5R6R7X−基团或—OSO2R12基团，以及它们与药物可接受的酸形成的加合物。